Connection

WOLFGANG WINKELMAYER to Dose-Response Relationship, Drug

This is a "connection" page, showing publications WOLFGANG WINKELMAYER has written about Dose-Response Relationship, Drug.
  1. A Phase II randomized controlled trial evaluated antithrombotic treatment with fesomersen in patients with kidney failure on hemodialysis. Kidney Int. 2024 07; 106(1):145-153.
    View in: PubMed
    Score: 0.168
  2. Thienopyridine use after coronary stenting in low income patients enrolled in medicare part D receiving maintenance dialysis. J Am Heart Assoc. 2014 Oct 21; 3(5):e001356.
    View in: PubMed
    Score: 0.087
  3. Correlates and variance decomposition analysis of heparin dosing for maintenance hemodialysis in older US patients. Pharmacoepidemiol Drug Saf. 2014 May; 23(5):515-25.
    View in: PubMed
    Score: 0.084
  4. IV iron dosing regimens: choice of agent and dosing frequency. Nephrol News Issues. 2014 Feb; 28(2):10-1, 18.
    View in: PubMed
    Score: 0.083
  5. Commentary on 'The DOPPS practice monitor for U.S. dialysis care: update on trends in anemia management 2 years into the bundle': iron(y) abounds 2 years later. Am J Kidney Dis. 2013 Dec; 62(6):1217-20.
    View in: PubMed
    Score: 0.082
  6. Use and safety of unfractionated heparin for anticoagulation during maintenance hemodialysis. Am J Kidney Dis. 2012 Sep; 60(3):473-86.
    View in: PubMed
    Score: 0.074
  7. Against TREATing all patients alike: lessons from an FDA Advisory Committee Meeting. J Am Soc Nephrol. 2011 Jan; 22(1):1-2.
    View in: PubMed
    Score: 0.067
  8. The challenges of cost-effectiveness analyses for the clinician. Am J Kidney Dis. 2010 Dec; 56(6):1023-5.
    View in: PubMed
    Score: 0.067
  9. Hydroxyethyl starch and change in renal function in patients undergoing coronary artery bypass graft surgery. Kidney Int. 2003 Sep; 64(3):1046-9.
    View in: PubMed
    Score: 0.040
  10. Warfarin utilisation and anticoagulation control in patients with atrial fibrillation and chronic kidney disease. Heart. 2017 06; 103(11):818-826.
    View in: PubMed
    Score: 0.025
  11. Comparative Effectiveness of Iron and Erythropoiesis-Stimulating Agent Dosing on Health-Related?Quality of Life in Patients Receiving?Hemodialysis. Am J Kidney Dis. 2016 Feb; 67(2):271-82.
    View in: PubMed
    Score: 0.023
  12. Intravenous iron supplementation practices and short-term risk of cardiovascular events in hemodialysis patients. PLoS One. 2013; 8(11):e78930.
    View in: PubMed
    Score: 0.020
  13. Angiotensin-converting enzyme inhibitor or angiotensin II type 1 receptor antagonist therapy is associated with prolonged patient and graft survival after renal transplantation. J Am Soc Nephrol. 2006 Mar; 17(3):889-99.
    View in: PubMed
    Score: 0.012
  14. The cost-effectiveness of maintaining higher hemoglobin targets with erythropoietin in hemodialysis patients. Kidney Int. 2003 Jul; 64(1):295-304.
    View in: PubMed
    Score: 0.010
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.